Literature DB >> 7875662

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients.

S Takano1, O Yokosuka, F Imazeki, M Tagawa, M Omata.   

Abstract

The incidence of hepatocellular carcinoma (HCC) was prospectively studied in 251 chronic hepatitis patients, and was compared between the 127 cases of hepatitis B and 124 cases of hepatitis C. All patients were diagnosed by needle biopsy on entering the study, and the cases consisted of chronic persistent hepatitis (CPH), chronic active hepatitis (CAH)2a, and CAH2b (cirrhosis was not included). Of the cases of chronic hepatitis B, 5 cases of HCC (3.9%) were detected; among the chronic hepatitis C cases, 13 cases (10.4%) were detected. Thus, although the mean follow-up periods were in the same range, the incidence of hepatocellular carcinoma was 2.7 times higher in hepatitis C than in hepatitis B (chi 2 = 3.116, P < .05). Using the Kaplan-Meier method, the incidence of HCC was significantly higher in chronic hepatitis C (P = .0194, generalized Wilcoxon test). In hepatitis C, the incubation period until HCC was detected was shorter when the liver disease was more advanced. Such a tendency was not observed in hepatitis B. In the 13 cases of HCC occurring in chronic hepatitis C, noncirrhotic liver was seen in only 1 case (7.7%), whereas 2 of the 5 cases of HCC (40%) in chronic hepatitis B were noncirrhotic. The prevalence of hepatitis C virus (HCV) genotypes II and III was the same in the total followed cases and HCC cases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875662

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  88 in total

1.  Telomere, telomerase and digestive cancer.

Authors:  Javed Yakoob; Guo-Ling Hu; Xue-Gong Fan; Zheng Zhang
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

2.  Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Authors:  Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; Hitoshi Asakura; Akira Naito; Shigeki Mori; Kojiro Hata; Kentaro Igarashi; Hidenori Hara; Hironobu Ohta; Kenji Soga; Toshiaki Watanabe; Tomoteru Kamimura
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

3.  Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement.

Authors:  Anthony E Samir; Manish Dhyani; Abhinav Vij; Atul K Bhan; Elkan F Halpern; Jorge Méndez-Navarro; Kathleen E Corey; Raymond T Chung
Journal:  Radiology       Date:  2014-11-13       Impact factor: 11.105

Review 4.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

5.  Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection.

Authors:  Kazumoto Murata; Kazushi Sugimoto; Katsuya Shiraki; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

6.  Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma.

Authors:  Fen-Yu Ren; Xi-Xu Piao; Ai-Lian Jin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

7.  Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy.

Authors:  Yukiko Ito; Natsuyo Yamamoto; Ryo Nakata; Yoshihisa Kato; Masashi Iori; Keisuke Sakai; Tamiko Takemura; Ryosuke Tateishi; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

8.  Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Authors:  Soocheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

9.  Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Soo Cheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

10.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.